Stewart Tepper

TitleAdjunct Faculty
InstitutionThomas Jefferson University
DepartmentNursing - Undergraduate
AddressNA
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Tepper SJ, Diamond ML, Hirman J, Asher D, Fiore D, Cady R. Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures. J Neurol. 2024 Dec 12; 272(1):4. PMID: 39666143.
      Citations:    
    2. Tepper SJ, Albrecht D, Ailani J, Kirby L, Strom S, Rapoport AM. Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study. CNS Drugs. 2024 Oct 07. PMID: 39373843.
      Citations:    
    3. Tepper SJ, Dodick DW, Lanteri-Minet M, Dolezil D, Gil-Gouveia R, Lucas C, Piasecka-Stryczynska K, Szab? G, Mikol DD, Chehrenama M, Chou DE, Yang Y, Paiva da Silva Lima G. Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial. JAMA Neurol. 2024 Sep 16. PMID: 39283627.
      Citations:    
    4. Khodavirdi AC, Multani JK, Oh SS, Vuvu F, Bensink ME, Stockl KM, Hawkins K, Chiang CC, Green AL, Tepper SJ. Treatment patterns of patients with migraine eligible for anti-CGRP pathway monoclonal antibodies. Front Neurol. 2024; 15:1433423. PMID: 39165264.
      Citations:    
    5. Lipton RB, Ailani J, Mullin K, Pavlovic JM, Tepper SJ, Dodick DW, Blumenfeld AM. Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks. Headache. 2024 Jul 03. PMID: 38957980.
      Citations:    
    6. Pozo-Rosich P, Ashina M, Tepper SJ, Jensen S, Boserup LP, Josiassen MK, Sperling B. Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study. Neurol Ther. 2024 Jan 18. PMID: 38236314.
      Citations:    
    7. D'Amico D, Grazzi L, Tepper SJ. Management of medication overuse headache. Handb Clin Neurol. 2024; 199:277-299. PMID: 38307652.
      Citations:    
    8. Ashina M, Tepper SJ, Gendolla A, Sperling B, Ettrup A, Josiassen MK, Starling AJ. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial. J Headache Pain. 2023 Nov 20; 24(1):155. PMID: 37985968.
      Citations:    
    9. Tepper SJ, Schwedt TJ, Vo P, Thompson J, Joshi P, Abdrabboh A, Ferraris M, Tiwari S. Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States. Headache. 2023 Sep 01. PMID: 37655551.
      Citations:    
    10. Blumenfeld AM, Lipton RB, Silberstein S, Tepper SJ, Charleston L, Landy S, Kuruvilla DE, Manack Adams A. Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review. Neurol Ther. 2023 Oct; 12(5):1533-1551. PMID: 37542624.
      Citations:    
    11. Li D, Abreu J, Tepper SJ. A Brief Review of Gepants. Curr Pain Headache Rep. 2023 Sep; 27(9):479-488. PMID: 37531032.
      Citations:    
    12. Tepper SJ, Lipton RB, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Wang A, Cheng S, Klatt J, Mikol DD. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis. Headache. 2023 Jun; 63(6):730-742. PMID: 37313616.
      Citations:    
    13. Tepper SJ, Cirillo J, Kim E, L'Italien G, Tweedie JM, Lodaya K, Riley D, Pathan F, Antaki N, Nathanson BH, McAllister P. The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression. J Headache Pain. 2023 May 16; 24(1):54. PMID: 37193973.
      Citations:    
    14. Tepper SJ, Dong Y, Vincent M, Wietecha LA. Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine. Headache. 2023 May 03. PMID: 37132481.
      Citations:    
    15. Jensen RH, Schytz HW, Tassorelli C, Terwindt GM, Carlsen LN, Mittoux A, ?sterberg O, Lipton RB, Tepper SJ, Blumenfeld A, Lundqvist C. Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION-A phase 4, multinational, randomized, double-blind, placebo-controlled study. Front Neurol. 2023; 14:1114654. PMID: 36908606.
      Citations:    
    16. Tepper SJ, Rabany L, Cowan RP, Smith TR, Grosberg BM, Torphy BD, Harris D, Vizel M, Ironi A, Stark-Inbar A, Blumenfeld AM. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache. 2023 Jan 27. PMID: 36704988.
      Citations:    
    17. Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023 Jan; 63(1):79-88. PMID: 36651532.
      Citations:    
    18. George N, Tepper SJ. Novel Migraine Treatments: A Review. J Oral Facial Pain Headache. 2023 Winter; 37(1):27-34. PMID: 36917235.
      Citations:    
    19. Tepper SJ, Ailani J, Ray S, Hirman J, Shrewsbury SB, Aurora SK. Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure. J Headache Pain. 2022 Nov 22; 23(1):148. PMID: 36414952.
      Citations:    
    20. Schoenen J, Snoer AH, Brandt RB, Fronczek R, Wei DY, Chung CS, Diener HC, Dodick DW, Fontaine D, Goadsby PJ, Matharu MS, May A, McGinley JS, Tepper SJ, Jensen RH, Ferrari MD. Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache. Cephalalgia. 2022 12; 42(14):1450-1466. PMID: 36268950.
      Citations:    
    21. Ailani J, Kaiser EA, Mathew PG, McAllister P, Russo AF, V?lez C, Ramajo AP, Abdrabboh A, Xu C, Rasmussen S, Tepper SJ. Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review. Neurology. 2022 Sep 20. PMID: 36127137.
      Citations:    
    22. Tepper SJ, Grosberg B, Daniel O, Kuruvilla DE, Vainstein G, Deutsch L, Sharon R. Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial. Headache. 2022 Jun 24. PMID: 35748757.
      Citations:    
    23. Daniel O, Tepper SJ, Deutsch L, Sharon R. External Concurrent Occipital and Trigeminal Neurostimulation Relieves Migraine Headache: A Prospective, Randomized, Double-Blind, Sham-Controlled Trial. Pain Ther. 2022 Jun 04. PMID: 35661128.
      Citations:    
    24. Ashina M, Tepper SJ, Brandes JL, Reuter U, Boudreau GP, Weatherall M, Gantenbein AR, Doležil D, Klatt J, Wang A, Karanam AK, Cheng S, Mikol DD. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. Headache. 2022 May; 62(5):624-633. PMID: 35593783.
      Citations:    
    25. Medrea I, Christie S, Tepper SJ, Thavorn K, Hutton B. Network meta-analysis of therapies for cluster headache: Effects of acute therapies for episodic and chronic cluster. Headache. 2022 04; 62(4):482-511. PMID: 35343597.
      Citations:    
    26. Kuruvilla DE, Mann JI, Tepper SJ, Starling AJ, Panza G, Johnson MAL. Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM). Sci Rep. 2022 03 24; 12(1):5110. PMID: 35332216.
      Citations:    
    27. Tepper SJ, Ailani J, Ford JH, Nichols RM, Li LQ, Kemmer P, Hand AL, Tockhorn-Heidenreich A. Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER). Clin Drug Investig. 2022 Mar 07. PMID: 35254628.
      Citations:    
    28. Medrea I, Christie S, Tepper SJ, Thavorn K, Hutton B. Effects of acute and preventive therapies for episodic and chronic cluster headache: A scoping review of the literature. Headache. 2022 Mar; 62(3):329-362. PMID: 35315067.
      Citations:    
    29. Tepper SJ, Sheikh HU, Dougherty CO, Nahas SJ, Winner PK, Karanam AK, Blumenfeld AM, Abdrabboh A, Rasmussen S, Weiss JL, Ailani J. Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations. Headache. 2022 Feb 09. PMID: 35137404.
      Citations:    
    30. Ashina M, Goadsby PJ, Dodick DW, Tepper SJ, Xue F, Zhang F, Brennan F, Paiva da Silva Lima G. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials. JAMA Neurol. 2022 02 01; 79(2):159-168. PMID: 34928306.
      Citations:    
    31. Tepper SJ, Ailani J, Ford JH, Nichols RM, Li LQ, Kemmer P, Hand AL, Tockhorn-Heidenreich A. Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER). Clin Drug Investig. 2022 Jan 18. PMID: 35041159.
      Citations:    
    32. Dodick DW, Tepper SJ, Ailani J, Pannacciulli N, Navetta MS, Loop B, Zhang F, Khodavirdi AC, Mann A, Abdrabboh A, Kalim J. Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data. Headache. 2021 Oct; 61(9):1411-1420. PMID: 34591982.
      Citations:    
    33. Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache. 2021 Oct; 61(9):1421-1431. PMID: 34551130.
      Citations:    
    34. Lipton RB, Baygani SK, Tepper SJ, Krege JH, Vasudeva R, Pearlman EM, Hauck PM, Loo LS. A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN. J Headache Pain. 2021 Aug 28; 22(1):101. PMID: 34454420.
      Citations:    
    35. Lipton RB, Munjal S, Tepper SJ, Iaconangelo C, Serrano D. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura. J Pain Res. 2021; 14:2529-2542. PMID: 34447267.
      Citations:    
    36. Tepper SJ, Lucas S, Ashina M, Schwedt TJ, Ailani J, Scanlon J, Klatt J, Chou DE, Wang A, Paiva da Silva Lima G. Timing and durability of response to erenumab in patients with chronic migraine. Headache. 2021 Sep; 61(8):1255-1263. PMID: 34363708.
      Citations:    
    37. Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, Bonner JH, Picard H, Cheng S, Chou DE, Zhang F, Klatt J, Mikol DD. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. J Headache Pain. 2021 Jul 23; 22(1):81. PMID: 34301173.
      Citations:    
    38. Joshi S, Tepper SJ, Lucas S, Rasmussen S, Nelson R. A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management. Headache. 2021 06; 61(6):838-853. PMID: 34214182.
      Citations:    
    39. Tepper SJ, Fang J, Zhou L, Shen Y, Vo P, Abdrabboh A, Glassberg MB, Ferraris M. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States. J Manag Care Spec Pharm. 2021 Sep; 27(9):1157-1170. PMID: 33998825.
      Citations:    
    40. Tepper SJ, Fang J, Vo P, Shen Y, Zhou L, Abdrabboh A, Glassberg M, Ferraris M. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study. J Headache Pain. 2021 Apr 19; 22(1):27. PMID: 33874884.
      Citations:    
    41. Lipton RB, Munjal S, Dodick DW, Tepper SJ, Serrano D, Iaconangelo C. Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial. J Pain Res. 2021; 14:549-560. PMID: 33658842.
      Citations:    
    42. Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Wilcox TK, Shah S, Tepper SJ, Dodick DW, Lipton RB. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study. Headache. 2021 Mar; 61(3):438-454. PMID: 33594686.
      Citations:    
    43. Tepper SJ, Lin T, Montal T, Ironi A, Dougherty C. Real-world Experience with Remote Electrical Neuromodulation in the Acute Treatment of Migraine. Pain Med. 2020 12 25; 21(12):3522-3529. PMID: 32935848.
      Citations:    
    44. Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. Headache. 2020 Dec 13. PMID: 33314079.
      Citations:    
    45. Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Zhang F, Rippon GA, Cheng S, Mikol DD. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia. 2021 Jan; 41(1):6-16. PMID: 33269951.
      Citations:    
    46. Blumenfeld AM, Stevanovic DM, Ortega M, Cohen JM, Seminerio MJ, Yang R, Jiang B, Tepper SJ. No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study. Headache. 2020 Nov; 60(10):2431-2443. PMID: 33009665.
      Citations:    
    47. Tepper SJ. Headache Currents Thanks You. Headache. 2020 Nov; 60(10):2653. PMID: 33017472.
      Citations:    
    48. Doty EG, Krege JH, Pohl G, Case M, Dowsett SA, Tepper SJ. Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant. Headache. 2020 Jul 22. PMID: 32700321.
      Citations:    
    49. Tepper SJ, Vasudeva R, Krege JH, Rathmann SS, Doty E, Vargas BB, Magis D, Komori M. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks. Headache. 2020 Jul 07. PMID: 32634275.
      Citations:    
    50. Tepper SJ, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia. 2020 Mar 26; 333102420912726. PMID: 32216456.
      Citations:    
    51. Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, Reuter U, Hong F, Klatt J, Zhang F, Cheng S, Picard H, Eisele O, Wang J, Latham JN, Mikol DD. Vascular safety of erenumab for migraine prevention. Neurology. 2020 02 04; 94(5):e497-e510. PMID: 31852816.
      Citations:    
    52. Tepper SJ, Silberstein SD, Rosen NL, Lipton RB, Dennehy EB, Dowsett SA, Doty E. The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings. Headache. 2020 Jan; 60(1):178-189. PMID: 31792964.
      Citations:    
    53. Schwedt TJ, Digre K, Tepper SJ, Spare NM, Ailani J, Birlea M, Burish M, Mechtler L, Gottschalk C, Quinn AM, McGillicuddy L, Bance L, Dumkrieger G, Chong CD, Dodick DW. The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort. Headache. 2019 Nov 22. PMID: 31755111.
      Citations:    
    54. Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y, Hong F, Klatt J, Mikol DD. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia. 2019 Dec; 39(14):1798-1808. PMID: 31707815.
      Citations:    
    55. Rapoport AM, Lin T, Tepper SJ. Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine. Headache. 2020 01; 60(1):229-234. PMID: 31913517.
      Citations:    
    56. Tepper SJ. Acute Treatment of Migraine. Neurol Clin. 2019 11; 37(4):727-742. PMID: 31563229.
      Citations:    
    57. Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2020 01; 60(1):58-70. PMID: 31647577.
      Citations:    
    58. Goadsby PJ, Tepper SJ, Watkins PB, Ayele G, Miceli R, Butler M, Severt L, Finnegan M, Szegedi A, Trugman JM, Jakate A. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults. Cephalalgia. 2019 Dec; 39(14):1753-1761. PMID: 31537107.
      Citations:    
    59. de Coo IF, Marin JC, Silberstein SD, Friedman DI, Gaul C, McClure CK, Tyagi A, Liebler E, Tepper SJ, Ferrari MD, Goadsby PJ. Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. Cephalalgia. 2019 Jul; 39(8):967-977. PMID: 31246132.
      Citations:    
    60. Tepper SJ, Krege JH, Lombard L, Asafu-Adjei JK, Dowsett SA, Raskin J, Buchanan AS, Friedman DI. Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials. Headache. 2019 07; 59(7):1052-1062. PMID: 31152441.
      Citations:    
    61. Tepper SJ. CGRP and headache: a brief review. Neurol Sci. 2019 May; 40(Suppl 1):99-105. PMID: 30835001.
      Citations:    
    62. Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology. 2019 May 07; 92(19):e2250-e2260. PMID: 30996060.
      Citations:    
    63. Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019 05 14; 92(20):e2309-e2320. PMID: 30996056.
      Citations:    
    64. Mansfield C, Gebben DJ, Sutphin J, Tepper SJ, Schwedt TJ, Sapra S, Shah N. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment. Headache. 2019 05; 59(5):715-726. PMID: 30861110.
      Citations:    
    65. Tepper SJ, Dodick DW, Schmidt PC, Kellerman DJ. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches. Headache. 2019 04; 59(4):509-517. PMID: 30698272.
      Citations:    
    66. Blumenfeld AM, Tepper SJ, Robbins LD, Manack Adams A, Buse DC, Orejudos A, D Silberstein S. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. J Neurol Neurosurg Psychiatry. 2019 03; 90(3):353-360. PMID: 30630956.
      Citations:    
    67. Tepper SJ. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache. 2018 11; 58 Suppl 3:276-290. PMID: 30403405.
      Citations:    
    68. Dodick DW, Tepper SJ, Lipton RB, Buse DC, Stewart WF, Bayliss M, Desai P, Sapra S, Anderson K, McInerney-Prichard E. Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine Tracker. Headache. 2018 Oct; 58(9):1358-1372. PMID: 30362524.
      Citations:    
    69. Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G, Boudreau GP, McAllister P, Vu T, Zhang F, Cheng S, Picard H, Wen S, Kahn J, Klatt J, Mikol D. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018 Oct 01; 19(1):92. PMID: 30276500.
      Citations:    
    70. Tepper SJ. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. 2018 11; 58 Suppl 3:238-275. PMID: 30242830.
      Citations:    
    71. Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018 09; 38(10):1622-1631. PMID: 30086681.
      Citations:    
    72. Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018 09; 38(10):1611-1621. PMID: 29984601.
      Citations:    
    73. Dodick DW, Tepper SJ, Friedman DI, Gelfand AA, Kellerman DJ, Schmidt PC. Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial. Headache. 2018 Jul; 58(7):986-992. PMID: 29782049.
      Citations:    
    74. Tepper SJ, Johnstone MR. Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine. Med Devices (Auckl). 2018; 11:147-156. PMID: 29760572.
      Citations:    
    75. Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, Villa G, Shah N, Tepper S, Dodick D. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018 Jul; 21(7):666-675. PMID: 29571276.
      Citations:    
    76. Tepper SJ. Editorial: Understanding Menstrual Migraine. Headache. 2018 04; 58(4):625. PMID: 29611189.
      Citations:    
    77. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States. Headache. 2018 May; 58(5):700-714. PMID: 29446063.
      Citations:    
    78. Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options-A Response. Headache. 2018 01; 58(1):147. PMID: 29292511.
      Citations:    
    79. Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018 Jan 01; 333102418762525. PMID: 29504483.
      Citations:    
    80. Tepper SJ. Editorial: Nutraceuticals and Occipital Nerve Blocks. Headache. 2017 11; 57(10):E25. PMID: 29124759.
      Citations:    
    81. Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ. The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations. Am J Manag Care. 2017 Nov; 23(17 Suppl):S326-S333. PMID: 29144718.
      Citations:    
    82. Spierings EL, Brandes JL, Kudrow DB, Weintraub J, Schmidt PC, Kellerman DJ, Tepper SJ. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia. 2018 02; 38(2):215-224. PMID: 29022755.
      Citations:    
    83. Tepper SJ, Friedman DI. Editorial: The Importance of the Idiopathic Intracranial Hypertension Treatment Trial. Headache. 2017 09; 57(8):1301-1302. PMID: 28850180.
      Citations:    
    84. Tepper SJ, Duplin J, Nye B, Tepper DE. Prescribing Oxygen for Cluster Headache: A Guide for the Provider. Headache. 2017 Oct; 57(9):1428-1430. PMID: 28857152.
      Citations:    
    85. O'Brien M, Ford JH, Aurora SK, Govindan S, Tepper DE, Tepper SJ. Economics of Inhaled Oxygen Use as an Acute Therapy for Cluster Headache in the United States of America. Headache. 2017 Oct; 57(9):1416-1427. PMID: 28842974.
      Citations:    
    86. Tepper SJ. The SUN Also Rises. Headache. 2017 06; 57(6):995-996. PMID: 28594125.
      Citations:    
    87. Silberstein S, Winner PK, McAllister PJ, Tepper SJ, Halker R, Mahmoud RA, Siffert J. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan. Headache. 2017 Jun; 57(6):862-876. PMID: 28497569.
      Citations:    
    88. Tepper SJ. Roosevelt's Headache. Headache. 2017 05; 57(5):829. PMID: 28444947.
      Citations:    
    89. Maasumi K, Tepper SJ, Rapoport AM. New treatments for headache. Neurol Sci. 2017 May; 38(Suppl 1):145-156. PMID: 28527051.
      Citations:    
    90. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun; 16(6):425-434. PMID: 28460892.
      Citations:    
    91. Tepper SJ, Caparso A. Sphenopalatine Ganglion (SPG): Stimulation Mechanism, Safety, and Efficacy. Headache. 2017 Apr; 57 Suppl 1:14-28. PMID: 28387016.
      Citations:    
    92. Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options: Review. Headache. 2017 Feb; 57(2):194-208. PMID: 27910087.
      Citations:    
    93. Thorlund K, Sun-Edelstein C, Druyts E, Kanters S, Ebrahim S, Bhambri R, Ramos E, Mills EJ, Lanteri-Minet M, Tepper S. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain. 2016 Dec; 17(1):107. PMID: 27882516.
      Citations:    
    94. Krymchantowski AV, Tepper SJ, Jevoux C, Valença M. Medication-Overuse Headache: Protocols and Outcomes in 149 Consecutive Patients in a Tertiary Brazilian Headache Center. Headache. 2017 Jan; 57(1):87-96. PMID: 27861826.
      Citations:    
    95. Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, Liebler EJ, Rubenstein Engel E, Tepper SJ. Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study. Headache. 2016 Sep; 56(8):1317-32. PMID: 27593728.
      Citations:    
    96. Krymchantowski AV, Tepper SJ, Jevoux C, Valença MM. Medication-Overuse Headache: Differences between Daily and Near-Daily Headache Patients. Brain Sci. 2016 Aug 15; 6(3). PMID: 27537917.
      Citations:    
    97. Tepper SJ. Editorial - Acupuncture and Drug Interactions. Headache. 2016 Jul; 56(7):1237. PMID: 27432629.
      Citations:    
    98. Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ. TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 05; 87(1):41-8. PMID: 27281531.
      Citations:    
    99. Tariq N, Estemalik E, Vij B, Kriegler JS, Tepper SJ, Stillman MJ. Long-Term Outcomes and Clinical Characteristics of Hypnic Headache Syndrome: 40 Patients Series From a Tertiary Referral Center. Headache. 2016 Apr; 56(4):717-24. PMID: 27015738.
      Citations:    
    100. Tariq N, Tepper SJ, Kriegler JS. Patent Foramen Ovale and Migraine: Closing the Debate--A Review. Headache. 2016 Mar; 56(3):462-78. PMID: 26952049.
      Citations:    
    101. Tepper SJ. Antiepilepsy Drugs in Migraine Prevention: Editorial. Headache. 2016 Mar; 56(3):601-2. PMID: 26926490.
      Citations:    
    102. Tepper SJ. Editorial--Indomethacin. Headache. 2016 Feb; 56(2):421. PMID: 26852900.
      Citations:    
    103. Tepper SJ. Cyclic vomiting syndrome, inborn errors of metabolism, migraine variants, episodic syndromes that may be associated with migraine, and other unusual pediatric headache syndromes. Headache. 2016 Jan; 56(1):205. PMID: 26790854.
      Citations:    
    104. Maasumi K, Thompson NR, Kriegler JS, Tepper SJ. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine. Headache. 2015 Oct; 55(9):1218-24. PMID: 26381856.
      Citations:    
    105. Tepper SJ. Alcohol, Tobacco, Triggers, and Headache Disorders. Headache. 2015 Jul-Aug; 55(7):1027. PMID: 26417623.
      Citations:    
    106. Vij B, Whipple MO, Tepper SJ, Mohabbat AB, Stillman M, Vincent A. Frequency of Migraine Headaches in Patients With Fibromyalgia. Headache. 2015 Jun; 55(6):860-5. PMID: 25994041.
      Citations:    
    107. Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, Shin P, Siffert J. AVP-825 Breath-Powered Intranasal Delivery System Containing 22?mg Sumatriptan Powder vs 100?mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks. Headache. 2015 May; 55(5):621-35. PMID: 25941016.
      Citations:    
    108. Tepper SJ. Chronic migraine and medication overuse headache. Headache. 2014 Jul-Aug; 54(7):1249-50. PMID: 24912551.
      Citations:    
    109. Messali AJ, Yang M, Gillard P, Tsai K, Tepper SJ, Bloudek LM, Kori SH. Treatment persistence and switching in triptan users: a systematic literature review. Headache. 2014 Jul-Aug; 54(7):1120-30. PMID: 24912394.
      Citations:    
    110. Tepper SJ. Editorial: complementary and Alternative Medicine (CAM), Ayurvedic medicine, and research into behavioral and mind/body interventions in headache. Headache. 2014 Jun; 54(6):1114. PMID: 24916597.
      Citations:    
    111. Tepper SJ. Idiopathic intracranial hypertension and low CSF pressure headaches. Headache. 2014 Feb; 54(2):387-8. PMID: 24512581.
      Citations:    
    112. Tepper SJ. Medication overuse headache. Headache. 2014 Jan; 54(1):203. PMID: 24400770.
      Citations:    
    113. Landy SH, Tepper SJ, Schweizer E, Almas M, Ramos E. Outcome for headache and pain-free nonresponders to treatment of the first attack: a pooled post-hoc analysis of four randomized trials of eletriptan 40 mg. Cephalalgia. 2014 Apr; 34(5):376-81. PMID: 24265285.
      Citations:    
    114. Tepper SJ. Editorial: traumatic brain injury (TBI), pain, and headache. Headache. 2013 Oct; 53(9):1517. PMID: 24090533.
      Citations:    
    115. Zheng Y, Tepper SJ, Covington EC, Mathews M, Scheman J. Retrospective outcome analyses for headaches in a pain rehabilitation interdisciplinary program. Headache. 2014 Mar; 54(3):520-7. PMID: 24001145.
      Citations:    
    116. Tepper SJ, Chen S, Reidenbach F, Rapoport AM. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013 Sep; 53 Suppl 2:62-71. PMID: 24024604.
      Citations:    
    117. Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache. 2013 Sep; 53 Suppl 2:43-53. PMID: 24024602.
      Citations:    
    118. Almas M, Tepper SJ, Landy S, Schweizer E, Ramos E. Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study. Cephalalgia. 2014 Feb; 34(2):126-35. PMID: 23946318.
      Citations:    
    119. Tepper SJ, Stillman MJ. Cluster headache: potential options for medically refractory patients (when all else fails). Headache. 2013 Jul-Aug; 53(7):1183-90. PMID: 23808603.
      Citations:    
    120. Tepper SJ. Clinical implications for breath-powered powder sumatriptan intranasal treatment. Headache. 2013 Sep; 53(8):1341-9. PMID: 23809006.
      Citations:    
    121. Peterlin BL, Tietjen GE, Gower BA, Ward TN, Tepper SJ, White LW, Dash PD, Hammond ER, Haythornthwaite JA. Ictal adiponectin levels in episodic migraineurs: a randomized pilot trial. Headache. 2013 Mar; 53(3):474-90. PMID: 23489216.
      Citations:    
    122. Stillman MJ, Tepper DE, Tepper SJ, Cho L. QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 2: review of headache medications, drug-drug interactions, QTc prolongation, and other arrhythmias. Headache. 2013 Jan; 53(1):217-224. PMID: 23216298.
      Citations:    
    123. Stillman MJ, Tepper S, Tepper DE, Cho L. QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case. Headache. 2013 Jan; 53(1):208-216. PMID: 23216317.
      Citations:    
    124. Landy SH, Tepper SJ, Wein T, Schweizer E, Ramos E. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan. Headache. 2013 Jan; 53(1):118-125. PMID: 23148799.
      Citations:    
    125. Lakhan SE, Avramut M, Tepper SJ. Structural and functional neuroimaging in migraine: insights from 3 decades of research. Headache. 2013 Jan; 53(1):46-66. PMID: 23094683.
      Citations:    
    126. Da Silva AN, Tepper SJ. Acute treatment of migraines. CNS Drugs. 2012 Oct 01; 26(10):823-39. PMID: 22823482.
      Citations:    
    127. Tepper SJ. Medication-overuse headache. Continuum (Minneap Minn). 2012 Aug; 18(4):807-22. PMID: 22868543.
      Citations:    
    128. Da Silva AN, Tepper SJ, Evans RW. Side-locked and side shifting primary headaches. Headache. 2012 Jul-Aug; 52(7):1178-83. PMID: 22724506.
      Citations:    
    129. Tepper SJ. Advanced interventions for headache. Headache. 2012 May; 52 Suppl 1:50-4. PMID: 22540208.
      Citations:    
    130. Tepper SJ. Opioids should not be used in migraine. Headache. 2012 May; 52 Suppl 1:30-4. PMID: 22540203.
      Citations:    
    131. Tepper SJ, Rothrock JF. Conclusions on opioids. Headache. 2012 May; 52 Suppl 1:38-9. PMID: 22540205.
      Citations:    
    132. Tepper SJ. Serotonin syndrome: SSRIs, SNRIs, triptans, and current clinical practice. Headache. 2012 Feb; 52(2):195-7. PMID: 22221260.
      Citations:    
    133. Baron EP, Moskowitz SI, Tepper SJ, Gupta R, Novak E, Hussain MS, Stillman MJ. Headache following intracranial neuroendovascular procedures. Headache. 2012 May; 52(5):739-48. PMID: 22211779.
      Citations:    
    134. Tepper SJ, Lowe MJ, Beall E, Phillips MD, Liu K, Stillman MJ, Horvat M, Jones SE. Iron deposition in pain-regulatory nuclei in episodic migraine and chronic daily headache by MRI. Headache. 2012 Feb; 52(2):236-43. PMID: 22188387.
      Citations:    
    135. Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT, Silberstein SD. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache. 2012 Jan; 52(1):37-47. PMID: 22106843.
      Citations:    
    136. Baron EP, Cherian N, Tepper SJ. Role of greater occipital nerve blocks and trigger point injections for patients with dizziness and headache. Neurologist. 2011 Nov; 17(6):312-7. PMID: 22045281.
      Citations:    
    137. Tepper SJ, Kori SH, Goadsby PJ, Winner PK, Wang MH, Silberstein SD, Cutrer FM. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc. 2011 Oct; 86(10):948-55. PMID: 21964172.
      Citations:    
    138. Jenkins B, Tepper SJ. Neurostimulation for primary headache disorders, part 1: pathophysiology and anatomy, history of neuromodulation in headache treatment, and review of peripheral neuromodulation in primary headaches. Headache. 2011 Sep; 51(8):1254-66. PMID: 21815889.
      Citations:    
    139. Jenkins B, Tepper SJ. Neurostimulation for primary headache disorders: Part 2, review of central neurostimulators for primary headache, overall therapeutic efficacy, safety, cost, patient selection, and future research in headache neuromodulation. Headache. 2011 Oct; 51(9):1408-18. PMID: 21812772.
      Citations:    
    140. Bamford CC, Mays M, Tepper SJ. Unusual headaches in the elderly. Curr Pain Headache Rep. 2011 Aug; 15(4):295-301. PMID: 21455737.
      Citations:    
    141. Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, Dodick DW. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011 Apr; 51(4):507-17. PMID: 21457235.
      Citations:    
    142. Whyte CA, Stillman MJ, Tepper SJ. Dihydroergotamine and its use in migraine with posterior fossa symptoms. Headache. 2010 Oct; 50(9):1419-23. PMID: 20533960.
      Citations:    
    143. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010 Jun; 50(6):1089-99. PMID: 20618823.
      Citations:    
    144. Blumenfeld A, Ashkenazi A, Grosberg B, Napchan U, Narouze S, Nett B, DePalma T, Rosenthal B, Tepper S, Lipton RB. Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: Results of the American Headache Society Interventional Procedure Survey (AHS-IPS). Headache. 2010 Jun; 50(6):937-42. PMID: 20618812.
      Citations:    
    145. Ashkenazi A, Blumenfeld A, Napchan U, Narouze S, Grosberg B, Nett R, DePalma T, Rosenthal B, Tepper S, Lipton RB. Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research. Headache. 2010 Jun; 50(6):943-52. PMID: 20487039.
      Citations:    
    146. Baron EP, Tepper SJ, Mays M, Cherian N. Acute treatment of basilar-type migraine with greater occipital nerve blockade. Headache. 2010 Jun; 50(6):1057-9. PMID: 20487035.
      Citations:    
    147. Ansarinia M, Rezai A, Tepper SJ, Steiner CP, Stump J, Stanton-Hicks M, Machado A, Narouze S. Electrical stimulation of sphenopalatine ganglion for acute treatment of cluster headaches. Headache. 2010 Jul; 50(7):1164-74. PMID: 20438584.
      Citations:    
    148. Tepper SJ, Tepper DE. Breaking the cycle of medication overuse headache. Cleve Clin J Med. 2010 Apr; 77(4):236-42. PMID: 20360117.
      Citations:    
    149. Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010 Sep; 50(8):1353-61. PMID: 20353432.
      Citations:    
    150. Whyte CA, Tepper SJ. Pearls & Oy-sters: trigeminal autonomic cephalalgias. Neurology. 2010 Mar 16; 74(11):e40-2. PMID: 20231659.
      Citations:    
    151. Whyte C, Tepper SJ, Evans RW. Expert opinion: Rescue me: rescue medication for migraine. Headache. 2010 Feb; 50(2):307-13. PMID: 20456134.
      Citations:    
    152. Tepper SJ. The role of prevention. Handb Clin Neurol. 2010; 97:195-205. PMID: 20816421.
      Citations:    
    153. Katic BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME. Adherence to acute migraine medication: what does it mean, why does it matter? Headache. 2010 Jan; 50(1):117-29. PMID: 19817884.
      Citations:    
    154. Tepper SJ, Cleves C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs. 2009 Jul; 10(7):711-20. PMID: 19579177.
      Citations:    
    155. Tepper SJ, Rezai A, Narouze S, Steiner C, Mohajer P, Ansarinia M. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache. 2009 Jul; 49(7):983-9. PMID: 19486173.
      Citations:    
    156. Kowacs PA, Piovesan EJ, Tepper SJ. Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache. 2009 Jul; 49(7):1022-7. PMID: 19438733.
      Citations:    
    157. Tepper SJ, Zatochill M, Szeto M, Sheftell F, Tepper DE, Bigal M. Development of a simple menstrual migraine screening tool for obstetric and gynecology clinics: the menstrual migraine assessment tool. Headache. 2008 Nov-Dec; 48(10):1419-25. PMID: 19076645.
      Citations:    
    158. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008 Oct; 48(9):1337-42. PMID: 19031499.
      Citations:    
    159. Bigal M, Sheftell F, Tepper S, Tepper D, Ho TW, Rapoport A. A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache. 2008 Oct; 48(9):1286-93. PMID: 19031496.
      Citations:    
    160. Tepper SJ, Stillman MJ. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache. 2008 Sep; 48(8):1259-68. PMID: 18808506.
      Citations:    
    161. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008 Sep; 7(5):587-96. PMID: 18759711.
      Citations:    
    162. Cleves C, Tepper SJ. Sumatriptan/naproxen sodium combination for the treatment of migraine. Expert Rev Neurother. 2008 Sep; 8(9):1289-97. PMID: 18759540.
      Citations:    
    163. Taylor FR, Tepper SJ, Stillman MJ. Recent studies on PFO and migraine: is there a future for closure? Headache. 2008 Jul; 48(7):1083-6. PMID: 18687080.
      Citations:    
    164. Tepper SJ. A pivotal moment in 50 years of headache history: the first American Migraine Study. Headache. 2008 May; 48(5):730-1; discussion 732. PMID: 18471125.
      Citations:    
    165. Tepper DE, Tepper SJ, Sheftell FD, Bigal ME. Headache attributed to hypothyroidism. Curr Pain Headache Rep. 2007 Aug; 11(4):304-9. PMID: 17686395.
      Citations:    
    166. Tepper SJ. Treatment of menstrual migraine: evidence-based review. Manag Care. 2007 Jul; 16(7 Suppl 7):10-4; discussion 15-7. PMID: 17927087.
      Citations:    
    167. Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007 Apr; 47(4):475-9. PMID: 17445096.
      Citations:    
    168. Loder E, Rizzoli P, McGeeney B, Ward T, Levin M, Shapiro RE, Tepper S, Newman L, Sheftell F, Rapoport A, Markley H. Cluster headache treatment dilemmas: the experts respond. Curr Pain Headache Rep. 2007 Apr; 11(2):141-7. PMID: 17367594.
      Citations:    
    169. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007 Feb; 47(2):266-9. PMID: 17300366.
      Citations:    
    170. Diener HC, Steiner TJ, Tepper SJ. Migraine--the forgotten epidemic: development of the EHF/WHA Rome Declaration on Migraine. J Headache Pain. 2006 Dec; 7(6):433-7. PMID: 17149560.
      Citations:    
    171. Sun C, Lay C, Broner S, Silberstein S, Tepper S, Newman L. Reversible anorgasmia with topiramate therapy for headache: a report of 7 patients. Headache. 2006 Oct; 46(9):1450-3. PMID: 17040342.
      Citations:    
    172. Tepper SJ. Tailoring management strategies for the patient with menstrual migraine: focus on prevention and treatment. Headache. 2006 Oct; 46 Suppl 2:S61-8. PMID: 17044843.
      Citations:    
    173. Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006 May; 46(5):766-72. PMID: 16643579.
      Citations:    
    174. Kilminster SG, Dowson AJ, Tepper SJ, Baos V, Baudet F, D'Amico D. Reliability, validity, and clinical utility of the Migraine-ACT questionnaire. Headache. 2006 Apr; 46(4):553-62. PMID: 16643548.
      Citations:    
    175. Vogler B, Rapoport AM, Tepper SJ, Sheftell F, Bigal ME. Role of melatonin in the pathophysiology of migraine: implications for treatment. CNS Drugs. 2006; 20(5):343-50. PMID: 16696576.
      Citations:    
    176. Tepper SJ, Cady R, Dodick D, Freitag FG, Hutchinson SL, Twomey C, Kuhn TA. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. Headache. 2006 Jan; 46(1):115-24. PMID: 16412159.
      Citations:    
    177. Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME. Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study. Headache. 2005 Nov-Dec; 45(10):1400-6. PMID: 16324173.
      Citations:    
    178. Volcy M, Sheftell FD, Tepper SJ, Rapoport AM, Bigal ME. Tinnitus in migraine: an allodynic symptom secondary to abnormal cortical functioning? Headache. 2005 Sep; 45(8):1083-7. PMID: 16109127.
      Citations:    
    179. Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME. Levetiracetam in the preventive treatmentof transformed migraine: A prospective, open-label, pilot study. Curr Ther Res Clin Exp. 2005 May; 66(3):212-21. PMID: 24672124.
      Citations:    
    180. Bigal ME, Rapoport AM, Tepper SJ, Sheftell FD, Lipton RB. The classification of chronic daily headache in adolescents--a comparison between the second edition of the international classification of headache disorders and alternative diagnostic criteria. Headache. 2005 May; 45(5):582-9. PMID: 15953277.
      Citations:    
    181. Sheftell FD, Feleppa M, Tepper SJ, Rapoport AM, Ciannella L, Bigal ME. Assessment of adverse events associated with triptans--methods of assessment influence the results. Headache. 2004 Nov-Dec; 44(10):978-82. PMID: 15546260.
      Citations:    
    182. Tepper SJ, Dahlöf CG, Dowson A, Newman L, Mansbach H, Jones M, Pham B, Webster C, Salonen R. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache. 2004 Oct; 44(9):856-64. PMID: 15447694.
      Citations:    
    183. Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache. 2004 Sep; 44(8):794-800. PMID: 15330826.
      Citations:    
    184. Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB. Chronic daily headache: correlation between the 2004 and the 1988 International Headache Society diagnostic criteria. Headache. 2004 Jul-Aug; 44(7):684-91. PMID: 15209691.
      Citations:    
    185. Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004 Jul-Aug; 44(7):661-8. PMID: 15209687.
      Citations:    
    186. Prince PB, Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME. The effect of weather on headache. Headache. 2004 Jun; 44(6):596-602. PMID: 15186304.
      Citations:    
    187. Dowson AJ, Cady RK, Tepper SJ, Smith TR, Shapero G. Pharmacologic management of migraine. Ann Intern Med. 2004 Mar 16; 140(6):W26. PMID: 15023737.
      Citations:    
    188. Tepper SJ. Treatment of headache pain with botulinum neurotoxins. Pain Pract. 2004 Mar; 4 Suppl 1:S38-46. PMID: 17129274.
      Citations:    
    189. Sheftell FD, Bigal ME, Tepper SJ, Rapoport AM. Sumatriptan: a decade of use and experience in the treatment of migraine. Expert Rev Neurother. 2004 Mar; 4(2):199-209. PMID: 15853561.
      Citations:    
    190. Sheftell FD, Tepper SJ, Rapoport AM. Analgesic use: a predictor of chronic pain in medication overuse headache: the Head-HUNT study. Neurology. 2004 Feb 24; 62(4):677; author reply 677. PMID: 14981203.
      Citations:    
    191. Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs. 2004; 18(10):671-85. PMID: 15270595.
      Citations:    
    192. Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Zolmitriptan (Zomig). Expert Rev Neurother. 2004 Jan; 4(1):33-41. PMID: 15853613.
      Citations:    
    193. Tepper SJ. An overview of migraine pathophysiology. Postgrad Med. 2003 Nov; 114(5 Suppl Understanding):5-10. PMID: 19667644.
      Citations:    
    194. Bigal ME, Rapoport AM, Bordini CA, Tepper SJ, Sheftell FD, Speciali JG. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache. 2003 Jul-Aug; 43(7):742-54. PMID: 12890129.
      Citations:    
    195. Rapoport AM, Bigal ME, Volcy M, Sheftell FD, Feleppa M, Tepper SJ. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. Headache. 2003 May; 43(5):482-9. PMID: 12752754.
      Citations:    
    196. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003 Apr; 43(4):336-42. PMID: 12656704.
      Citations:    
    197. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003 Mar; 2(2):123-32. PMID: 12904112.
      Citations:    
    198. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ. New migraine preventive options: an update with pathophysiological considerations. Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec; 57(6):293-8. PMID: 12612763.
      Citations:    
    199. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003 Feb; 7(1):55-62. PMID: 12525272.
      Citations:    
    200. Antoniazzi AL, Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Headache and hemodialysis: a prospective study. Headache. 2003 Feb; 43(2):99-102. PMID: 12558762.
      Citations:    
    201. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations : how to match patients and products. CNS Drugs. 2003; 17(6):431-47. PMID: 12697002.
      Citations:    
    202. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache. 2003 Jan; 43(1):44-8. PMID: 12864757.
      Citations:    
    203. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache. 2002 Oct; 42(9):862-71. PMID: 12390611.
      Citations:    
    204. Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM. Hemicrania continua: a report of ten new cases. Arq Neuropsiquiatr. 2002 Sep; 60(3-B):695-8. PMID: 12364931.
      Citations:    
    205. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002 Jul; 59(7):1084-8. PMID: 12117355.
      Citations:    
    206. Bigal ME, Sheftell FD, Rapoport AM, Tepper SJ, Lipton RB. Chronic daily headache: identification of factors associated with induction and transformation. Headache. 2002 Jul-Aug; 42(7):575-81. PMID: 12482208.
      Citations:    
    207. Tepper SJ. Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is a cause of chronic daily headache. Headache. 2002 Jun; 42(6):543-7. PMID: 12167148.
      Citations:    
    208. Tepper SJ, Rapoport AM, Sheftell FD. Ethical considerations in cluster headache research. Curr Pain Headache Rep. 2002 Feb; 6(1):47-51. PMID: 11749877.
      Citations:    
    209. Sheftell FD, Tepper SJ. New paradigms in the recognition and acute treatment of migraine. Headache. 2002 Jan; 42(1):58-69. PMID: 12005277.
      Citations:    
    Tepper's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (394)
    Explore
    _
    Co-Authors (6)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _